amiodarone has been researched along with Familial Hypokalemic Periodic Paralysis in 1 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atienza Morales, MP | 1 |
| Jiménez García, JA | 1 |
| Beato Pérez, JL | 1 |
| Aguilar Campos, AJ | 1 |
1 other study available for amiodarone and Familial Hypokalemic Periodic Paralysis
| Article | Year |
|---|---|
[Amiodarone as cause of Periodic thyrotoxic hypopotasemic paralysis].
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Humans; Hypokalemic Periodic Paralysis; Male; Treatment O | 2006 |